Biotech Breakthroughs: 8 New Paths in Mental Health Treatment

In my work, I have leveraged biotechnology primarily through pharmacogenomic testing to help guide medication selection and dosing with more precision. This approach can reduce the trial-and-error period by clarifying how an individual may metabolize or respond to certain psychiatric medications. It also supports clearer, more collaborative conversations with patients about why one option may be a better fit than another. The most promising direction that deserves further exploration is expanding the responsible, evidence-based use of pharmacogenomics in everyday psychiatric care. That includes refining how test results are interpreted alongside a person’s symptoms, medical history, and treatment goals. With thoughtful integration, pharmacogenomics has the potential to make treatment decisions more targeted while keeping care centered on the individual sitting in front of us.

Data feeds panic when continuously being monitored.

I actually have my patients use smartwatches to monitor the physiological surges they experience during exposure therapy.

In this day and age, there is a global trend of millions of people constantly checking their heart rates, treating normal fluctuations as some type of medical emergency.

Although it was not intentional, the growing culture of constant bio-surveillance has unintentionally caused a major increase in health anxiety.

The next area of development for consumer biotechnology will be collecting this data and then using it to create insights about past events.

When reviewing your patient’s device logs within 20 minutes of experiencing an anxiety attack, it provides objective proof to the anxious brain that their heart rate returned to a normal state by itself (without needing any assistance).

Over the course of 3-4 anxiety attacks, the concept that the adrenaline experienced is going to cause harm can begin to be broken down through visualizing how the body reacted in each instance.

I want to be straight with you about the framing, because I would rather be useful than just agree with the premise. I am not a biotech person, and the company I run is not a biotech play. I am the co-founder and CTO of a nationwide therapy network, so my work in mental health is on the technology and delivery side, the platform, the matching, the access, rather than on biology or pharmacology.

What I can speak to with some authority is the thing biotech tends to overshadow. In mental health specifically, the bottleneck for most people is not the science, it is access. There are effective treatments that already exist that huge numbers of people never reach, because the system is hard to navigate, the wait is long, the match between patient and clinician is poor, and the whole experience is built for the system rather than the person. The most underleveraged technology in this field is not a new molecule, it is the unglamorous infrastructure that gets the right person to the right clinician quickly and keeps them engaged once they are there.

So the direction I think deserves far more attention is delivery, not discovery. We pour enormous excitement into biotech breakthroughs while the much larger, more immediate gains are sitting in logistics, intake, matching, and follow through. Across our network, the difference between someone getting better and someone giving up often has nothing to do with the treatment itself and everything to do with whether the path to it was navigable. That is a solvable problem with technology that exists today, and it would help more people, faster, than most of what gets called innovation in this space.

As a psychiatric provider, I believe biotechnology has already transformed mental health care in meaningful ways, particularly through advances in neuroscience, genetics, digital health tools, and medication development. While psychiatry still relies heavily on clinical evaluation and patient history, biotech is helping us move toward more personalized and data-driven treatment approaches.

One area I have found particularly valuable is the use of telepsychiatry and digital monitoring tools. These technologies make mental health care more accessible, allow for closer follow-up, and help patients stay engaged in treatment regardless of their location. For many individuals, especially those in underserved communities, this can be a significant step toward better outcomes.

I am also encouraged by ongoing research into biomarkers and precision psychiatry. Currently, selecting psychiatric medications often involves a degree of trial and error because individuals respond differently to treatment. The ability to identify biological markers that predict treatment response could help providers make more informed decisions and reduce the time patients spend searching for an effective medication.

Another promising direction is the growing understanding of the connection between physical health and mental health. Research exploring inflammation, the gut-brain axis, and immune system function may provide new insights into conditions such as depression, anxiety, and bipolar disorder. These findings could eventually lead to innovative treatment options beyond traditional psychiatric medications.

If I had to identify one area that deserves more exploration, it would be personalized mental health treatment based on a combination of genetic, biological, and clinical data. The future of psychiatry may not be about finding a single treatment that works for everyone, but rather understanding what works best for each individual patient. That shift has the potential to improve outcomes, reduce suffering, and make mental health care more effective and precise.